Following a full submission:
risankizumab (Skyrizi®) is accepted for restricted use within NHSScotland.
Indication under review: for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
SMC restriction: for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.
Risankizumab was superior to placebo, a tumour necrosis factor antagonist, and an interleukin 12/23 antagonist in improving symptoms of adult patients with moderate to severe plaque psoriasis.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of risankizumab. This SMC advice is contingent upon the continuing availability of the patient access scheme, or a list price that is equivalent or lower, in NHSScotland.
- Medicine name:
- risankizumab (Skyrizi)
- SMC ID:
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Submission type
- Date advice published:
- 07 October 2019